Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Revenue (2016 - 2025)

Avalo Therapeutics filings provide 10 years of Revenue readings, the most recent being $59000.0 for Q4 2025.

  • On a quarterly basis, Revenue fell 69.27% to $59000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $500000.0, a 13.38% increase, with the full-year FY2025 number at $59000.0, down 86.62% from a year prior.
  • Revenue hit $59000.0 in Q4 2025 for Avalo Therapeutics, down from $192000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $14.9 million in Q3 2022 to a low of $59000.0 in Q4 2025.
  • Median Revenue over the past 5 years was $571000.0 (2023), compared with a mean of $1.7 million.
  • Biggest five-year swings in Revenue: skyrocketed 1007.33% in 2022 and later plummeted 98.42% in 2023.
  • Avalo Therapeutics' Revenue stood at $219000.0 in 2021, then skyrocketed by 309.13% to $896000.0 in 2022, then crashed by 36.27% to $571000.0 in 2023, then crashed by 66.37% to $192000.0 in 2024, then tumbled by 69.27% to $59000.0 in 2025.
  • The last three reported values for Revenue were $59000.0 (Q4 2025), $192000.0 (Q4 2024), and $249000.0 (Q3 2024) per Business Quant data.